Rejuvenation Technologies, Inc.
Publicly observedMountain View, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | Mountain View | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Rejuvenation Technologies, Inc. | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | T6RGDB42JZN6 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant1 Jul 2026Publicly observed
NIH SBIR/STTR award: Advancing a telomere extension biologic to treat alcohol-associated liver damage to IND
USD 2,063,303.00 · National Institute on Alcohol Abuse and Alcoholism · Source: NIH RePORTER (opens in a new tab)
- Grant1 Aug 2024Publicly observed
NIH SBIR/STTR award: Advanced tools for translation of intravenously-infused RNA LNP therapeutics to the clinic
USD 1,065,587.00 · National Center for Advancing Translational Sciences · Source: NIH RePORTER (opens in a new tab)
- Grant1 Aug 2024Publicly observed
NIH SBIR/STTR award: Advanced tools for translation of intravenously-infused RNA LNP therapeutics to the clinic
USD 1.00 · National Center for Advancing Translational Sciences · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.